文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

肠易激综合征的粪便微生物群移植：系统评价和荟萃分析。

Fecal microbiota transplantation in irritable bowel syndrome: A systematic review and meta-analysis.

机构信息

Department of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, USA.

Laboratorio de Hígado, Páncreas y Motilidad (HIPAM)-Unit of Research in Experimental Medicine, Faculty of Medicine, Universidad Nacional Autónoma de México (UNAM), Hospital General de México, Dr. Eduardo Liceaga, Mexico City, Mexico.

出版信息

United European Gastroenterol J. 2019 Oct;7(8):1033-1041. doi: 10.1177/2050640619866990. Epub 2019 Jul 30.

DOI:10.1177/2050640619866990
PMID:31662860
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6794695/
Abstract

BACKGROUND: Modulating gut microbiota is a potential treatment for irritable bowel syndrome (IBS). This meta-analysis explored whether fecal microbiota transplantation (FMT) is successful in treating IBS. METHODS: A systematic review was performed to find trials on FMT in IBS. Ratios and relative ratios (RR) of improvement for single-arm trials (SATs) and randomized controlled trials (RCTs) were calculated, respectively. Changes in IBS Severity Scoring System (IBS-SSS) and IBS Quality of Life (IBS-QOL) instrument compared to baseline in FMT versus placebo groups were pooled. RESULTS: In SATs, 59.5% (95% confidence interval (CI) 49.1-69.3) of IBS patients showed significant improvement. In RCTs, there were no differences between FMT and control in improvement (RR=0.93 (95% CI 0.50-1.75)) or changes in the IBS-SSS and IBS-QOL. CONCLUSIONS: FMT was not effective in IBS. Variations in FMT methods and patient factors may contribute to the heterogeneous results of the trials.

摘要

背景：调节肠道微生物群是治疗肠易激综合征（IBS）的一种潜在方法。本荟萃分析探讨了粪便微生物群移植（FMT）治疗 IBS 是否有效。

方法：系统检索了关于 FMT 治疗 IBS 的试验。分别计算了单臂试验（SAT）和随机对照试验（RCT）的改善率比值和相对比值（RR）。比较 FMT 组与安慰剂组治疗前后 IBS 严重程度评分系统（IBS-SSS）和 IBS 生活质量（IBS-QOL）量表的变化。

结果：在 SAT 中，59.5%（95%置信区间（CI）49.1-69.3）的 IBS 患者有显著改善。在 RCT 中，FMT 与对照组在改善率（RR=0.93（95% CI 0.50-1.75））或 IBS-SSS 和 IBS-QOL 量表的变化方面无差异。

结论：FMT 对 IBS 无效。FMT 方法和患者因素的差异可能导致试验结果存在异质性。

相似文献

[1]
Fecal microbiota transplantation in irritable bowel syndrome: A systematic review and meta-analysis.

United European Gastroenterol J. 2019-7-30

[2]
A meta-analysis of randomized controlled trials evaluating the effectiveness of fecal microbiota transplantation for patients with irritable bowel syndrome.

BMC Gastroenterol. 2024-7-5

[3]
Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis.

Am J Gastroenterol. 2019-7

[4]
Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Meta-Analysis of Randomized Controlled Trials.

Front Cell Infect Microbiol. 2022

[5]
Fecal microbiota transplantation for irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.

Front Immunol. 2023

[6]
Fecal microbiota transplantation for the treatment of irritable bowel syndrome: A systematic review and meta-analysis.

World J Gastroenterol. 2023-5-28

[7]
Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study.

Gut. 2018-7-6

[8]
Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome.

Aliment Pharmacol Ther. 2020-4-28

[9]
Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome.

Aliment Pharmacol Ther. 2019-5-28

[10]
The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation.

PLoS One. 2018-11-14

引用本文的文献

[1]
Microbial Metabolite Effects on Vasculogenic Mimicry in Metastatic Cancers.

Cells. 2025-5-30

[2]
Impact of Microbiota on Irritable Bowel Syndrome Pathogenesis and Management: A Narrative Review.

Medicina (Kaunas). 2025-1-13

[3]
FMT and TCM to treat diarrhoeal irritable bowel syndrome with induced spleen deficiency syndrome- microbiomic and metabolomic insights.

BMC Microbiol. 2024-10-26

[4]
Changes in Fecal Short-Chain Fatty Acids in IBS Patients and Effects of Different Interventions: A Systematic Review and Meta-Analysis.

Nutrients. 2024-5-31

[5]
Exploring the role of gut microbiota in advancing personalized medicine.

Front Microbiol. 2023-11-30

[6]
The gut microbiome dysbiosis and regulation by fecal microbiota transplantation: umbrella review.

Front Microbiol. 2023-11-3

[7]
Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Int J Mol Sci. 2023-9-26

[8]
Alterations in fecal β-defensin-3 secretion as a marker of instability of the gut microbiota.

Gut Microbes. 2023

[9]
How the interplay among the tumor microenvironment and the gut microbiota influences the stemness of colorectal cancer cells.

World J Stem Cells. 2023-5-26

[10]
Fecal microbiota transplantation for irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.

Front Immunol. 2023

本文引用的文献

[1]
Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial.

Gastroenterology. 2021-1

[2]
The Effect of Allogenic Versus Autologous Fecal Microbiota Transfer on Symptoms, Visceral Perception and Fecal and Mucosal Microbiota in Irritable Bowel Syndrome: A Randomized Controlled Study.

Clin Transl Gastroenterol. 2019-4

[3]
Fecal microbiota transplantation for treatment of recurrent C. difficile infection: An updated randomized controlled trial meta-analysis.

PLoS One. 2019-1-23

[4]
A randomized double-blind placebo-controlled trial showing rifaximin to improve constipation by reducing methane production and accelerating colon transit: A pilot study.

Indian J Gastroenterol. 2018-9

[5]
Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: A randomized clinical trial.

PLoS One. 2018-11-2

[6]
Fecal microbiota transfer for bowel disorders: efficacy or hype?

Curr Opin Pharmacol. 2018-9-12

[7]
Fecal Microbiota Transplantation: Current Status in Treatment of GI and Liver Disease.

Clin Gastroenterol Hepatol. 2018-7-25

[8]
Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study.

Gut. 2018-7-6

[9]
Dysbiosis in Functional Bowel Disorders.

Ann Nutr Metab. 2018-4-25

[10]
Fecal microbiota transplantation as a possible treatment of irritable bowel syndrome.

Ann Transl Med. 2017-12

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索